Cabaletta Bio Revenue and Competitors

Location

#6002

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Cabaletta Bio's estimated annual revenue is currently $11M per year.(i)
  • Cabaletta Bio's estimated revenue per employee is $75,377
  • Cabaletta Bio's total funding is $88M.
  • Cabaletta Bio's current valuation is $93.8M. (January 2022)

Employee Data

  • Cabaletta Bio has 146 Employees.(i)
  • Cabaletta Bio grew their employee count by 68% last year.

Cabaletta Bio's People

NameTitleEmail/Phone
1
Executive Director, New Product Planning and Business DevelopmentReveal Email/Phone
2
VP and Head Clinical OperationsReveal Email/Phone
3
VP, GMP Quality & ComplianceReveal Email/Phone
4
VP Regulatory AffairsReveal Email/Phone
5
VP & ControllerReveal Email/Phone
6
General CounselReveal Email/Phone
7
Director Information Technology and Data SciencesReveal Email/Phone
8
Director, Clinical ScientistReveal Email/Phone
9
Associate Director, Clinical OperationsReveal Email/Phone
10
Director GCP ComplianceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Cabaletta Bio?

Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabalettaᅢᄁ¬ツᆲ¬トᄁs therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The platform is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop the CAAR T technology to treat B cell-mediated autoimmune diseases. The Companyᅢᄁ¬ツᆲ¬トᄁs lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris (mPV), which is a rare skin disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. The IND for the lead product candidate, DSG3-CAART, was accepted in September 2019 and was granted Fast Track Designation by the FDA in May 2020. The Phase 1 clinical trial for DSG3-CAART is now open for recruitment.

keywords:N/A

$88M

Total Funding

146

Number of Employees

$11M

Revenue (est)

68%

Employee Growth %

$93.8M

Valuation

N/A

Accelerator

Cabaletta Bio News

2022-04-17 - CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff ...

CLASS ACTION CASE DETAILS: The filed complaint alleges that Cabaletta Bio, Inc. made materially false and/or misleading statements and/or failed...

2022-04-17 - 2022-04-21 | NDAQ:CABA | Press Release | Cabaletta Bio Inc.

CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline.

2022-03-22 - CABALETTA BIO, INC. CLASS ACTION ALERT: Wolf ...

CABALETTA BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been...

2019-01-09 - Cabaletta Bio Closes $50M Series B Financing

Cabaletta Bio Inc., a Radnor, PA-based biotechnology company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases, closed a $50m Series B financing. Backers included new investors Deerfield Management Company, Boxer Capital of Tavistock Group, Red ...

2019-01-06 - Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

Radnor, Pennsylvania-based Cabaletta previously closed a $38 million Series A funding round in May. The company said at the time that it planned to file an Investigational New Drug application for its lead product candidate in the second half of this year. The company is developing what it call ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46.1M146N/AN/A
#2
$47.2M1486%N/A
#3
$40.7M148-2%N/A
#4
$53.7M1489%N/A
#5
$7.5M1493%N/A